生理钙腹膜透析液对钙磷代谢达标及血管钙化影响的研究-东南大学学报医学版

生理钙腹膜透析液对钙磷代谢达标及血管钙化影响的研究

单位：1. 南京医科大学鼓楼临床医学院肾内科, 江苏南京 210008;
2. 南京大学医学院附属鼓楼医院肾内科, 江苏南京 210008

分类号：R459.5

出版年·卷·期（页码）：2017·36·第六期（1009-1014）

摘要：

目的：探讨生理钙腹膜透析对患者钙磷代谢紊乱和心血管钙化的影响。方法：2009年1月至2015年6月在我院规律随访大于12个月的134例腹膜透析患者，根据使用透析液钙离子浓度不同分为高钙透析组、生理钙透析组。比较患者治疗12个月前后的钙磷代谢情况、心脏超声及血管钙化等相关指标。结果：71例高钙透析组患者在治疗12个月后，其血钙水平显著高于使用生理钙透析组的58例患者（P<0.01）。高钙透析组患者在治疗12个月后，其血钙、冠脉积分、腹主动脉积分水平较基线水平升高程度显著高于生理钙透析组患者（P<0.05）。5例患者随访中由高钙透析液转为生理钙透析液，在更换为生理钙透析液治疗12个月后，患者血钙显著降低、iPTH明显升高（P<0.05）。与高钙透析组患者比较，生理钙透析组和高钙转生理钙透析组患者在治疗12个月后，活性维生素D的使用和血钙达标的比例显著高于前者（P<0.05）。高钙转生理钙透析液的5例患者在改用生理钙透析液后患者的iPTH达标率显著增加（P<0.05）。结论：与高钙透析液相比，使用生理钙透析液有利于维持腹膜透析患者血钙的达标，改善iPTH代谢，并延缓血管钙化的进程。

Objective: To investigate the calcium-phosphorus metabolism and cardiovascular system in patients using physiological calcium peritoneal dialysis fluid. Methods: A total of 134 peritoneal dialysis patients who had been followed-up for more than 12 months were divided into high calcium dialysis group and physiological calcium dialysis group according to the types of dialysate they used. After 12 months of treatment, the general situation, serum levels of calcium and phosphorus and the indices of cardiac ultrasound and vascular calcification were compared between the two groups. Results: After 12 months of treatment, the serum calcium level was significantly increased in high calcium dialysis group (P<0.01).The increments of serum calcium, calcification scores of coronary arteries and abdominal aorta were more prominent in the high calcium dialysis group than those in the physiological calcium dialysis group (P<0.05). For the 5 patients who had changed their dialysate from high calcium to physical calcium, the 12-month treatment of physical calcium dialysate made their serum calcium significantly decreased and the iPTH level markedly increased (P<0.05). As compared with the patients in high calcium group, those in physical calcium group and the five patients who had switched to physical calcium dialysate had a higher proportions of vitamin D administration and a more ideal serum calcium level. After patients replaced their dialysis therapy from high calcium dialysate to physical calcium dialysate,the standard-reaching rate of serum iPTH and calcium increased. Conclusions: Physical calcium dialysate are helpful for the patients to maintain ideal serum calcium and improve iPTH variation, and delay the aggregation of vascular calcification.

参考文献：

[1] WEINREICH T, PASSLICK-DEETJEN J, RITZ E, et al. Low dialysate calcium in continuous ambulatory peritoneal dialysis:a randomized controlled multicenter trial. The peritoneal dialysis multicenter study group[J]. Am J Kidney Dis,1995,25(3):452.
[2] WEINREICH T, RITZ E, PASSLICK-DEETJEN J. Long-term dialysis with low-calcium solution (1.0 mmol·L^-1) in CAPD:effects on bone mineral metabolism. Collaborators of the multicenter study group[J]. Perit Dial Int, 1996,16(3):260.
[3] GOLDSMITH D J A, COVIC A, FOUQUE D, et al. Endorsement of the kidney disease improving global outcomes (KDIGO) chronic kidney disease-mineral and bone Disorder (CKD-MBD) guidelines:a European renal best practice (ERBP) commentary statement[J]. Nephrol Dial Transplant,2010,25(12):3823-3831.
[4] WEINREICH T, PASSLICK-DEETJEN J, RITZ E. Low dialysate calcium in continuous ambulatory peritoneal dialysis:a randomized controlled multicenter trial. The peritoneal dialysis multicenter study group[J]. Am J Kidney Dis, 1995,25(3):452-460.
[5] 林爱武, 钱家麒, 庞慧华, 等. 长期使用低钙透析液对腹膜透析患者钙磷代谢的影响[J]. 中华肾脏病杂志,2005,21(12):713-715.
[6] BENDER F H, BERNARDINI J, PIRAINO B. Calcium mass transfer with dialysate containing 1.25 and 1.75 mmol·L^-1 calcium in peritoneal dialysis patients[J]. Am J Kidney Dis. 1992,20(4):367-71.
[7] BRANDI L, NIELSEN P K, BRO S, et al. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol·L^-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis[J]. J Intern Med,1998,244(2):121-131.
[8] MAO NZ, UEDA N, ゲイセ. Chapter 1:Introduction and definition of CKD|[ndash]|MBD and the development of the guideline statements[J]. Kidney Int,2009,76(5):S3-S130.
[9] 李芸, 朱彤莹, 田菁, 等. 低钙透析液对腹膜透析患者动力缺失性骨病的治疗[J]复旦大学学报:医学版,2007,34(2):213-215.
[10] 刘楠梅, 田军, 张金元, 等. 低钙透析液对腹膜透析患者颈动脉粥样硬化的影响[J]. 肾脏病与透析肾移植杂志,2008,17(2):119-122.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录